Tonya S. Joseph

Array ( [id] => 17290870 [patent_doc_number] => 20210386709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2 [patent_app_type] => utility [patent_app_number] => 17/319500 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198600 [patent_doc_number] => 20210338694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => SOS1 ALLOSTERIC SITE TARGETING [patent_app_type] => utility [patent_app_number] => 17/306646 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075833 [patent_doc_number] => 20220401445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => METHODS OF USING ALK2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/246577 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522889 [patent_doc_number] => 20230233538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => COMPOSITION FOR TREATING CORONAVIRUS DISEASE-19, COMPRISING PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID DERIVATIVES, OPTICAL ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 18/042801 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198572 [patent_doc_number] => 20210338666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => BRIMONIDINE COMBINATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/244094 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418487 [patent_doc_number] => 20230172945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES [patent_app_type] => utility [patent_app_number] => 17/920731 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522926 [patent_doc_number] => 20230233576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE [patent_app_type] => utility [patent_app_number] => 17/918973 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185179 [patent_doc_number] => 20210332064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/220307 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991763 [patent_doc_number] => 20210230183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/212737 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124379 [patent_doc_number] => 20210299147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => SLEEP AID AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 17/197395 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18361528 [patent_doc_number] => 20230143119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DIABETES AND METABOLIC DISEASES ASSOCIATED THEREWITH [patent_app_type] => utility [patent_app_number] => 17/905918 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18283732 [patent_doc_number] => 20230099204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER IN WHICH KRAS MUTATION AND ACTIVATED RON ARE PRESENT [patent_app_type] => utility [patent_app_number] => 17/800141 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18286720 [patent_doc_number] => 20230102192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE [patent_app_type] => utility [patent_app_number] => 17/799597 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790381 [patent_doc_number] => 20220249472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => ADMINISTRATION OF ANTIPSYCHOTICS [patent_app_type] => utility [patent_app_number] => 17/173841 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18269197 [patent_doc_number] => 20230090439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => PHARMACEUTICAL COMPOSITION FOR CONTROLLING PARASITES ON NON-HUMAN ORGANISMS [patent_app_type] => utility [patent_app_number] => 17/795652 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17795652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244666 [patent_doc_number] => 20230076977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => UTROPHIN UPREGULATION COMPOUNDS FOR DUCHENNE MUSCULAR DYSTROPHY THERAPY [patent_app_type] => utility [patent_app_number] => 17/792707 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18221721 [patent_doc_number] => 20230060715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS [patent_app_type] => utility [patent_app_number] => 17/787956 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981091 [patent_doc_number] => 20220347127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE [patent_app_type] => utility [patent_app_number] => 17/146013 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312770 [patent_doc_number] => 20210401818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => SYNERGISTIC ANTI-INFLAMMATORY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/126380 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399467 [patent_doc_number] => 20220041557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => DEUTERATED CFTR POTENTIATORS [patent_app_type] => utility [patent_app_number] => 17/120681 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17120681 [rel_patent_id] =>[rel_patent_doc_number] =>)